Dyne Therapeutics, Inc.
DYNDrugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Jun 30, 2026
9dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
NDA Filing - z-rostudirsen
For Duchenne muscular dystrophy. Dyne Therapeutics plans to file for FDA approval of z-rostudirsen, its Duchenne exon-skipping therapy, in the second half of 2026, supported by sustained long-term efficacy data. The filing timeline may benefit from the departure of controversial FDA CBER chief Vinay Prasad.
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
zeleciment basivarsen (DYNE-101)
Myotonic Dystrophy Type 1 (DM1)
Zeleciment Rostudirsen (DYNE-251)
Duchenne Muscular Dystrophy (DMD)
DYNE-101
Myotonic Dystrophy Type 1 (DM1)
DYNE-251
Duchenne Muscular Dystrophy (DMD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
zeleciment basivarsen (DYNE-101) | Phase 3 | Myotonic Dystrophy Type 1 (DM1) | - | - |
Zeleciment Rostudirsen (DYNE-251) | Phase 3 | Duchenne Muscular Dystrophy (DMD) | - | - |
DYNE-101 | Phase 2 | Myotonic Dystrophy Type 1 (DM1) | - | - |
DYNE-251 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |